Thymosin Alpha-1 Plus Chemotherapy in Gastric Cancer: Short-Term Gains, Weak Evidence
This meta-analysis quantifies response, immune, and tolerability signals for thymosin alpha-1 added to chemotherapy in gastric cancer, but the evidence base is small, Chinese-only, and of low certainty, limiting pharmacist confidence in routine use.
Thymosin alpha-1 boosts chemotherapy efficacy and safety in gastric cancer.
Improving efficacy and safety of chemotherapy regimens for gastric cancer can significantly enhance patient outcomes and quality of life. Thymosin alpha-1 with chemotherapy improved overall response rate, disease control rate, immune markers, and reduced adverse reactions, but long-term survival benefits are unclear. While thymosin alpha-1 shows promise, findings are based on low-quality, small studies from China; more research is needed to confirm these results. Thymosin alpha-1 combined with chemotherapy may improve short-term outcomes and safety in gastric cancer, but more high-quality studies are needed.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Wang Z, Sun T, Qu H, Zhao R, Shan X, Liu Y, Zheng Y
Citation:Wang Z, Sun T, Qu H, et al. Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials. Frontiers in immunology. 2026;17:1884797. doi:10.3389/fimmu.2026.1884797
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.